Bill seeks exclusivity for added orphan indications
This article was originally published in Scrip
Executive Summary
Drug makers with approved medicines on the US market could earn an extra six months of exclusivity protection for their products if the companies are able to show the drugs work to prevent, diagnose or treat a rare disease or condition if Congress adopts a new bill, which was introduced in the House by Representative Gus Bilirakis (Republican-Florida).